Advances in the management of acute myeloid leukaemia
Tracks
Track 1
| Tuesday, April 30, 2024 |
| 2:15 PM - 3:45 PM |
| Hall 1B |
Details
The treatment landscape of acute myeloid leukaemia (AML) continues to evolve. In this session new treatment options for patients with newly diagnosed and relapsed AML will be discussed including the pivotal role of clinical trials and the development of a UK AML Registry.
Speaker
Prof. Steve Knapper
Consultant Haematologist
Cardiff University
Optimising chemotherapy options in fit adults with acute myeloid leukaemia
Dr. Mike Dennis
Consultant Haematologist
The Christie NHS Foundation Trust
Expanding treatment options in unfit adults with AML
Dr Pramila Krishnamurthy
Consultant Haematologist
King's College Hospital
Management of Relapsed AML
Dr. Priyanka Mehta
Consultant Haematologist
University Hospitals of Bristol and Weston NHS Trust
The development of a UK AML registry
Chair
Charles Craddock
Professor Of Haemato-oncology
Warwick Clinical Trials Unit
